Keybank National Association OH lowered its stake in Johnson & Johnson (NYSE:JNJ) by 0.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,497,677 shares of the company’s stock after selling 11,235 shares during the period. Johnson & Johnson makes up approximately 1.2% of Keybank National Association OH’s portfolio, making the stock its 15th biggest holding. Keybank National Association OH owned about 0.06% of Johnson & Johnson worth $210,619,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in JNJ. Geode Capital Management LLC grew its holdings in Johnson & Johnson by 1.5% during the first quarter. Geode Capital Management LLC now owns 38,965,156 shares of the company’s stock worth $5,100,421,000 after acquiring an additional 572,077 shares during the period. Wellington Management Group LLP grew its holdings in Johnson & Johnson by 10.8% during the first quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock worth $4,006,895,000 after acquiring an additional 2,968,879 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Johnson & Johnson by 7.7% during the first quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock worth $3,871,753,000 after acquiring an additional 2,118,870 shares during the period. Capital World Investors grew its holdings in Johnson & Johnson by 182.9% during the first quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock worth $2,779,435,000 after acquiring an additional 13,703,905 shares during the period. Finally, Morgan Stanley grew its holdings in Johnson & Johnson by 0.3% during the first quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock worth $2,727,694,000 after acquiring an additional 54,563 shares during the period. 68.44% of the stock is currently owned by institutional investors and hedge funds.
In related news, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the transaction, the executive vice president now directly owns 21,682 shares in the company, valued at $3,197,444.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.27% of the company’s stock.
NYSE JNJ opened at $152.06 on Wednesday. The business’s 50-day moving average price is $147.76 and its 200 day moving average price is $144.18. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $157.00. The company has a market capitalization of $400.58 billion, a PE ratio of 22.23, a price-to-earnings-growth ratio of 3.37 and a beta of 0.68. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.40.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The firm had revenue of $18.34 billion for the quarter, compared to the consensus estimate of $17.73 billion. During the same period in the prior year, the business posted $2.58 earnings per share. The firm’s revenue for the quarter was down 10.8% compared to the same quarter last year. Equities analysts predict that Johnson & Johnson will post 7.85 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be given a dividend of $1.01 per share. The ex-dividend date of this dividend is Monday, August 24th. This represents a $4.04 annualized dividend and a yield of 2.66%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: Mutual Funds
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.